Published: Hepatic Oncology, 2021
Aim
To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.
Materials & methods
Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.
Results
From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.
Conclusions
Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.
Keywords
BCLC stage; ECOG performance status; hepatocellular carcinoma; immuno-oncology agent; similarity assessment; systemic treatment.
